MRNA logo

Moderna, Inc.

MRNA
Healthcare|Biotechnology|US
$254.19
+12.73 (+5.27%)
Tangible Book / Share
$17.05
Cash / Share
$12.90

Analyst Consensus

Hold29 analysts
Strong Buy
0
Buy
7
Hold
16
Sell
6
Strong Sell
0
Consensus Target
$132.70
Implied Upside
-47.8%
Low Target
$25.00
High Target
$245.00

Price Target Trend

Last Month
$183.50
2 targets · -28% vs price
Last Quarter
$153.30
10 targets · -40% vs price
Last Year
$72.94
33 targets · -71% vs price
All Time
$118.47
97 targets · -53% vs price

Rating Trend

Dec 25
6 buy · 16 hold · 3 sell
Jan 26
5 buy · 18 hold · 3 sell
Feb 26
4 buy · 18 hold · 3 sell
Mar 26
4 buy · 18 hold · 3 sell
Apr 26
4 buy · 18 hold · 3 sell
May 26
4 buy · 17 hold · 4 sell
Jun 26
4 buy · 17 hold · 4 sell
Jul 26
4 buy · 17 hold · 4 sell
Aug 26
6 buy · 18 hold · 3 sell
Sep 26
5 buy · 17 hold · 3 sell
Oct 26
5 buy · 16 hold · 4 sell
Nov 26
4 buy · 16 hold · 4 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 26, 2026Piper Sandler$230.00(+15%)$200.10TheFly
Oct 15, 2026Goldman SachsSalveen Richter$137.00(-39%)$226.30TheFly
Sep 3, 2026UBS$81.00(-46%)$150.81TheFly
Aug 28, 2026Argus ResearchJohn Eade$180.00(+26%)$142.77StreetInsider
Aug 24, 2026BarclaysEliana Merle$125.00(-14%)$145.13TheFly
Aug 20, 2026UBSMichael Yee$150.00(-14%)$174.38TheFly
Aug 19, 2026Goldman Sachs$120.00(-31%)$174.38TheFly
Aug 19, 2026RBC CapitalLuca Issi$130.00(-14%)$151.30TheFly
Aug 19, 2026Loop Capital MarketsLeah Rush Cann$135.00(-3%)$139.12StreetInsider
Aug 19, 2026D.A. DavidsonMichael Baker$245.00(+77%)$138.21StreetInsider
Jul 21, 2026Goldman Sachs$67.00(+13%)$59.49TheFly
Jul 20, 2026Wolfe ResearchAlexandria Hammond$25.00(-60%)$61.82StreetInsider
Jul 8, 2026Morgan Stanley$39.00(-51%)$79.77TheFly
Jul 7, 2026RBC Capital$45.00(-45%)$81.80TheFly
Jun 26, 2026Piper Sandler$77.00(+14%)$67.66TheFly
May 4, 2026UBS$45.00(-5%)$47.47TheFly
May 4, 2026RBC CapitalLuca Issi$38.00(-19%)$46.87TheFly
May 1, 2026Goldman Sachs$49.00(+8%)$45.37TheFly
May 1, 2026Morgan Stanley$33.00(-25%)$44.18TheFly
Mar 3, 2026JefferiesAndrew Tsai$37.00(-26%)$49.83StreetInsider

Recent Rating Actions

FirmActionRatingDate
William BlairdowngradeOutperform →Market PerformOct 27, 2026
Piper SandlermaintainOverweightOct 26, 2026
TD CowenmaintainHoldOct 21, 2026
Goldman SachsmaintainNeutralOct 15, 2026
Morgan StanleymaintainEqual WeightOct 7, 2026
CitigroupdowngradeNeutral →SellSep 30, 2026
Rothschild & CodowngradeNeutral →SellSep 3, 2026
Argus ResearchupgradeHold →BuyAug 28, 2026
Wolfe ResearchupgradeUnderperform →Peer PerformAug 25, 2026
BarclaysmaintainEqual WeightAug 24, 2026
JP MorganmaintainUnderweightAug 21, 2026
UBSmaintainNeutralAug 20, 2026
Goldman SachsmaintainNeutralAug 20, 2026
Morgan StanleymaintainEqual WeightAug 20, 2026
William BlairupgradeMarket Perform →OutperformAug 19, 2026
CitigroupmaintainNeutralAug 3, 2026
Goldman SachsmaintainNeutralJul 21, 2026
Morgan StanleymaintainEqual WeightJul 8, 2026
B of A SecuritiesmaintainUnderperformJul 7, 2026
RBC CapitalmaintainSector PerformJul 7, 2026
Piper SandlermaintainOverweightJun 26, 2026
B of A SecuritiesmaintainUnderperformJun 8, 2026
Evercore ISI GroupmaintainIn LineMay 4, 2026
Goldman SachsmaintainNeutralMay 4, 2026
UBSmaintainNeutralMay 4, 2026

Earnings History

Next report: Feb 12, 2027 · EPS est. $-1.73
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 6, 2026$0.38$-1.10$1.31B$890.3M
Jul 31, 2026$-1.97$-2.03$145.0M$102.9M
May 1, 2026$-3.40$-4.45$389.0M$236.4M
Feb 13, 2026$-2.11$-2.54$678.0M$635.2M
Nov 6, 2025$-0.51$-1.87$1.02B$920.9M
Aug 1, 2025$-2.13$-2.99$142.0M$893.3M
May 1, 2025$-2.52$-2.92$107.0M$116.7M
Feb 14, 2025$-2.50$-2.68$956.0M$942.8M

News

Moderna: 3 Key Takeaways for Long-Term Investors

Moderna raised full-year 2026 revenue growth guidance to 15% to 25%. Intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3.

Nov 8, 2026fool.com
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?

Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.

Nov 6, 2026zacks.com
Moderna, Inc. (MRNA) Q3 2026 Earnings Call Transcript

Moderna, Inc. ( MRNA ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Chief Financial Officer Stephen Hoge - President David Berman - Chief Development Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Edward Tenthoff - …

Nov 6, 2026seekingalpha.com
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.

Nov 6, 2026zacks.com
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

Nov 6, 2026reuters.com
Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction

Revenue jumped 29% on international COVID vaccine sales tied to long-term government deals. Moderna raised its 2026 revenue growth outlook to 15% to 25%.

Nov 6, 2026fool.com
Great Jobs Report. Will It Matter to Market Participants?

BLS results were far better than expected: +165K, close to triple the +59K analysts were looking for.

Nov 6, 2026zacks.com
What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna NASDAQ: MRNA raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results.

Nov 6, 2026marketbeat.com
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher

A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.

Nov 6, 2026247wallst.com
Moderna Stock Pops, Taps Multi-Year High After Earnings

Moderna (NASDAQ:MRNA) stock was last seen up 3.9% to trade at $250.95 after reporting third-quarter earnings of $0.38 per share on $1.3 billion in revenue, versus Wall Street estimates of a loss of $1.25 per share on roughly $882 million in revenue.

Nov 6, 2026schaeffersresearch.com
Moderna Just Gave Investors Yet Another Thing to Cheer About

Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D budget.

Nov 6, 2026fool.com
Nasdaq Futures Jump as Volatile Week Continues

Stock futures are trading mixed as Wall Street digests today's nonfarm payrolls data and yesterday's steep selloff

Nov 6, 2026schaeffersresearch.com
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates

Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.

Nov 6, 2026zacks.com
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.

Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.

Nov 6, 2026barrons.com
Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit

The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.

Nov 6, 2026wsj.com
Moderna's stock jumps after biotech raises sales outlook

The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.

Nov 6, 2026marketwatch.com
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas

Nov 6 (Reuters) - Moderna (MRNA.

Nov 6, 2026reuters.com
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth.   The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

Nov 6, 2026cnbc.com
6,541 Shares of Moderna, Inc. $MRNA Purchased by Caldwell Trust Co

Caldwell Trust Co acquired a new stake in shares of Moderna, Inc. (NASDAQ: MRNA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,541 shares of the company's stock, valued at approximately $1,260,000. A number of other

Nov 6, 2026defenseworld.net
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.

Nov 6, 2026benzinga.com